Abbott Faces New Trial Over Infant Formula Causing Deadly Disease; Prior Verdicts Reached $495M
summarizeSummary
Abbott Laboratories is set to face a new trial in Chicago over claims that its premature infant formula caused necrotizing enterocolitis (NEC), a potentially deadly bowel disease. This trial, which consolidates four lawsuits and begins with jury selection, is part of nearly 1,000 lawsuits filed against Abbott and Mead Johnson concerning these claims. While Abbott's recent 10-K (2026-02-20) disclosed "substantial ongoing legal battles over infant formula," the commencement of a specific trial represents a new, near-term legal catalyst. Previous trials have yielded mixed results, including a $495 million verdict against Abbott and a $60 million verdict against Mead Johnson, both currently under appeal. The outcome of this trial could influence future litigation, potentially leading to further significant financial liabilities and reputational damage for the company. Investors will closely monitor the trial's progress and verdict to assess the ongoing financial and legal exposure.
At the time of this announcement, ABT was trading at $113.68 on NYSE in the Life Sciences sector, with a market capitalization of approximately $197.4B. The 52-week trading range was $105.27 to $141.23. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.